Objective To explore the effect of the combined sequential application of er-lotinib between the chemotherapy periods on the treatment of the patients with advanced non small cell lung cancer (NSCLC).Methods 45 patients with advanced NSCLC were collected.The pa-tients with the initial treatment were treated with gemcitabine combined with platinum for chemotherapy,while the patients with retreatment were treated with docetaxel or pemetrexed for chemotherapy.Between the chemotherapy periods,the sequential erlotinib therapy was applied to all the patients.The short-term efficacy and the adverse reactions were evaluated and compared. Results The clinical efficacy of the initial treatment patients and the retreatment patients were 27.6% and 18.8% respectively (P >0.05),and the clinical control rate of the initial treatment patients was significantly higher than that of the retreatment patients (P <0.05).The clinical ef-ficacy of the patients with a history of smoking was significantly lower than that of the patients without a history of smoking (P <0.05).The clinical efficacy of the initial treatment patients with age over 65 years old was significantly higher than that of the initial treatment patients with age less than 65 years old(P <0.05).The clinical efficacy of the initial treatment patients with stage Ⅲ b was significantly higher than that of the initial treatment patients with stage Ⅳ (P <0.05).The clinical efficacy of the retreatment patients with adenocarcinoma pathological type was significantly higher than that of the patients without adenocarcinoma pathological type (P <0 .0 5 ).The main adverse reactions were nausea ,diarrhea ,rash ,vomiting and loss of appetite . Conclusion The clinical efficacy of the combined sequential application of erlotinib between the chemotherapy periods in the treatment of the patients with advanced NSCLC is not such high. Smoking history,age,tumor stage and pathological type may affect its curative effect.Efficacy of this therapy in controlling the disease progress of the initial treatment patients is significant,the adverse reactions are mild,and the tolerance of the patients for the therapy is higher.%目的：探讨化疗间期联合序贯应用厄洛替尼治疗晚期非小细胞肺癌（NSCLC）的疗效。方法选取晚期 NSCLC患者45例，初治患者应用吉西他滨联合铂类进行化疗，复治患者应用多西他赛或培美曲塞进行化疗，在化疗间期应用厄洛替尼进行序贯治疗。对患者的近期疗效和毒副反应进行评价和比较。结果初治患者和复治患者的临床有效率分别为27．6％和18．8％（P ＞0．05），初治患者的临床控制率显著高于复治患者（P ＜0．05）；具有吸烟史患者的临床有效率显著低于无吸烟史的患者（P ＜0．05）；年龄≥65岁的初治患者的临床有效率显著高于年龄＜65的初治患者（P ＜0．05）；Ⅲb 期的初治患者的临床有效率显著高于Ⅳ期的初治患者（P ＜0．05）；病理类型为腺癌的复治患者的临床有效率显著高于病理类型为非腺癌的复治患者（P ＜0．05）；患者的主要不良反应为皮疹、恶心、腹泻、呕吐、食欲减退等。结论化疗间期联合序贯应用厄洛替尼治疗晚期 NSCLC 的临床有效率并不高，吸烟史、年龄、肿瘤分期、病理类型都可能对其疗效产生影响，该疗法在控制初治患者病情进展方面效果较显著，且不良反应较轻，患者的可耐受度较高。
展开▼
